Narsoplimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MASP2, Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP-2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity.
Biosimilars
Human
Monoclonal
Human
MASP2
Human
IgG4 Lambda
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
CAS Number 2108782-45-0
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más